Taysha Gene Therapies (NASDAQ:TSHA) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Taysha Gene Therapies (NASDAQ:TSHA) had its price target hoisted by investment analysts at Citizens Jmp from $8.00 to $11.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s target price indicates a potential upside of 68.45% from the stock’s previous close.

Other analysts have also issued reports about the stock. Canaccord Genuity Group upped their price target on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, April 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Friday, March 27th. Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a research note on Tuesday. Bank of America reiterated a “buy” rating on shares of Taysha Gene Therapies in a report on Monday. Finally, Wall Street Zen cut shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $11.91.

Taysha Gene Therapies Trading Up 1.7%

TSHA stock opened at $6.53 on Tuesday. The company has a market capitalization of $1.88 billion, a PE ratio of -17.18 and a beta of 1.19. The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.04 and a current ratio of 14.04. Taysha Gene Therapies has a one year low of $2.25 and a one year high of $7.30. The company’s 50 day moving average price is $5.98 and its two-hundred day moving average price is $5.25.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). As a group, analysts predict that Taysha Gene Therapies will post -0.5 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $4.46, for a total transaction of $892,000.00. Following the transaction, the insider directly owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. The trade was a 14.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.78% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

Several large investors have recently added to or reduced their stakes in TSHA. Militia Capital Management LLC bought a new position in Taysha Gene Therapies in the 1st quarter worth $208,000. Seven Fleet Capital Management LP boosted its stake in shares of Taysha Gene Therapies by 274.2% during the 1st quarter. Seven Fleet Capital Management LP now owns 625,708 shares of the company’s stock valued at $2,797,000 after purchasing an additional 458,485 shares in the last quarter. Bank of America Corp DE increased its position in shares of Taysha Gene Therapies by 45.5% during the first quarter. Bank of America Corp DE now owns 1,677,046 shares of the company’s stock valued at $7,496,000 after buying an additional 524,366 shares during the period. ADAR1 Capital Management LLC raised its stake in Taysha Gene Therapies by 19.4% in the first quarter. ADAR1 Capital Management LLC now owns 2,979,429 shares of the company’s stock worth $13,318,000 after buying an additional 483,620 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Taysha Gene Therapies by 48.1% in the first quarter. The Manufacturers Life Insurance Company now owns 99,371 shares of the company’s stock worth $444,000 after buying an additional 32,286 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.